Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Breast Neoplasms × STA 9090 × Clear all

Phase

Status

Sponsor Class

OTHER 5 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Myeloproliferative Disorders 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

Trastuzumab 190 Paclitaxel 166 Fulvestrant 141 Capecitabine 136 Docetaxel 122 Letrozole 114 exemestane 79 palbociclib 67 Lapatinib 67 Anastrozole 65 Bevacizumab 62 Gemcitabine 61 Cyclophosphamide 61 pertuzumab 55 pembrolizumab 54 ribociclib 51 Carboplatin 49 abemaciclib 47 eribulin 44 Doxorubicin 38 Vinorelbine 37 Ado-Trastuzumab Emtansine 36 Tamoxifen 34 Everolimus 34 130-nm albumin-bound paclitaxel 31 Injections 29 trastuzumab deruxtecan 28 Albumin-Bound Paclitaxel 25 pegfilgrastim 22 Goserelin 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01677455 2015-11-05

Enchant

Synta Pharmaceuticals Corp.

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡